Branch C L, Burton G, Clarke G J, Coulton S, Douglas J D, Eglington A J, Guest A W, Hinks J D, Hird N W, Holland R K, Hunt E, Knott S J, Moss S F, Naylor A, Pearson M J, Takle A K
SmithKline Beecham Pharmaceuticals, Betchworth, Surrey, UK.
J Antibiot (Tokyo). 1998 Feb;51(2):210-20. doi: 10.7164/antibiotics.51.210.
The synthesis, antibacterial activity, and stability to human dehydropeptidase-1 (DHP-1) of a novel series of (5R,6S)-6-[(1R)-1-hydroxyethyl]-2-heterocyclylcarbapen-2-em-3-carb oxylates are described. Of the compounds investigated 1,5-disubstituted pyrazol-3-yl and 3-substituted isoxazol-5-yl derivatives have the best combination of antibacterial activity and stability to DHP-1. They are particularly active against community-acquired respiratory tract pathogens and have stabilities to DHP-1 superior to that of meropenem.